Shopping Cart
Remove All
Your shopping cart is currently empty
USP25/28 inhibitor AZ1 is a selective, orally active and non-competitive dual ubiquitin-specific protease USP25/28 inhibitor with IC50 of 0.7 μM and 0.6 μM, respectively, and exhibits anti-inflammatory and anti-tumor effects.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | In Stock | In Stock | |
| 5 mg | $64 | In Stock | In Stock | |
| 10 mg | $98 | In Stock | In Stock | |
| 25 mg | $222 | In Stock | In Stock | |
| 50 mg | $338 | In Stock | In Stock | |
| 100 mg | $497 | In Stock | In Stock | |
| 500 mg | $1,090 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $71 | In Stock | In Stock |
| Description | USP25/28 inhibitor AZ1 is a selective, orally active and non-competitive dual ubiquitin-specific protease USP25/28 inhibitor with IC50 of 0.7 μM and 0.6 μM, respectively, and exhibits anti-inflammatory and anti-tumor effects. |
| Targets&IC50 | USP28:0.6 nM, USP25:0.7 nM |
| In vitro | METHODS: HCT116 cells were treated with USP25/28 inhibitor AZ1 (20, 40, 60, 80, 100 μM) and samples were collected 3 hours later for Western blot analysis of USP28, c-Myc and PARP. RESULTS Western blot analysis showed that the total protein level of c-Myc decreased rapidly and concentration-dependently after treatment with USP25/28 inhibitor AZ1. [1] |
| In vivo | Method: USP25/28 inhibitor AZ1 (AZ1) (20, 40mg/kg, gavage) was given to WT Model mice were used to study the effect of USP25/28 inhibitor AZ1 (AZ1) on DSS-induced colitis. RESULTS USP25/28 inhibitor AZ1 (AZ1) treatment significantly reduced the number of colon tumors; the expression of wnt-related genes and pSTAT3 levels in tumors in the USP25/28 inhibitor AZ1 (AZ1) treatment group were reduced, and the SOCS3 level was increased; USP25/28 inhibitor Inflammation and bacterial replication were impaired in the colon of mice gavaged with AZ1 (AZ1), the expression of pro-inflammatory cytokines and antimicrobial peptides was enhanced, p-p65 and p-p38 levels were increased, and TRAF3 levels were decreased. [2] |
| Synonyms | AZ1 |
| Molecular Weight | 422.21 |
| Formula | C17H16BrF4NO2 |
| Cas No. | 2165322-94-9 |
| Smiles | OCCNCc1cc(Br)ccc1OCc1ccc(F)c(c1)C(F)(F)F |
| Relative Density. | 1.488 g/cm3 (Predicted) |
| Color | White |
| Appearance | solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (592.12 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (11.84 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.